SIGNIFICANCE OF MONOCYTE CHEMOATTRACTANT PROTEIN-1, THYROID HORMONES AND OTHER CLINICAL MANIFESTATIONS IN IRAQI PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME
Objective: Polycystic ovarian syndrome (PCOS) is a complex disease occurred throw genital period of women depends on the age, genetic factors, and ethnicity. Monocyte Chemoattractant Protein-1 (MCP-1) has been implicated in the metabolic disturbances and menstrual irregularities.
Methods: In the biochemical test, the blood was collected in plain tubes then separated by centrifugation. Serum was collected in test tubes then, MCP, haemoglobin (Hb), packed cell volume (PCV), fasting blood glucose (FBG), urea, creatinine, prolactin, testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), T3, T4, and thyroid-stimulating hormone (TSH) were determined by enzyme-linked immune-sorbent assay and relevant clinical features were collected simultaneously in all subjects.
Results: The results showed no significant increased in means of age, body mass index in PCOS women (patients) when compared with healthy subjects (control groups) also there was no significant decreased in levels of Hb, PCV while increased in FBG, urea and creatinine in PCOS women when compared with healthy subjects. In addition, mean of LH and 17 Î²-Estradiol were no significant increased except the significantly increased in the ratio of LH/FSH, prolactin, and testosterone, while FSH was significantly decreased in PCOS women when compared with healthy subjects. Levels of triiodothyronine (T3) and thyroxine (T4) were found significantly decreased while an increased level of TSH when compared with healthy subjects. Finally, MCP-1 was showed significantly increased in PCOS women when compared with healthy subjects.
Conclusions: It can be concluded that PCOS women might suffer from changes in the levels of MCP-1(an inflammation marker). Besides, it was detected that TSH might be responsible related metabolic disturbances could be related to TSH and MCP which can be considered as relevant features in such disturbances.
2. Anbu J, Jayaraman A, Krishnan S, Shivalingappa SK, Reddy RP, Nandihalli VB, et al. Effect of Sargassum ilicifolium on ovogenesis in polycystic ovary syndrome-induced rats. Asian J Pharm Clin Res 2016;9:127-31.
3. Al-Deresawi MS, AlFaisal AH. Detection of five substitution TPO mutations in polycystic ovary syndrome (PCOS) and thyroid hormones disturbance patients. J Biotechnol Res Center 2014;8:5-15.
4. Zaki M, Hassan N, El-Bassyouni HT, Kamal S, Basha W, Azmy O, et al. Association of the Pro12Ala polymorphism with the metabolic parameters in women with polycystic ovary syndrome. Open Access Maced J Med Sci 2017;5:275-80.
5. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: An updated overview. Front Physiol 2016;7:124.
6. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: An update. Reprod Biol Endocrinol 2016;14:38.
7. Murri M, Luque-RamÃrez M, Insenser M, Ojeda-Ojeda M, Escobar- Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Hum Reprod Update 2013;19:268-88.
8. Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic ovary syndrome: Insights into the therapeutic approach with inositols. Front Pharmacol 2017;8:1-13.
9. HÃ¸jlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Dan Med J 2014;61:B4890.
10. Cadagan D, Khan R, Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod Biol 2016;16:53-60.
11. Homer MV, Rosencrantz MA, Shayya RF, Chang RJ. The effect of estradiol on granulosa cell responses to FSH in women with polycystic ovary syndrome. Reprod Biol Endocrinol 2017;15:1-6.
12. Al-Jefout M, Alnawaiseh N, Al-Qtaitat A. Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. Sci Rep 2017;7:1-9.
13. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013;6:1-13.
14. Pergialiotis V, Konstantopoulos P, Prodromidou A, Florou V, Papantoniou N, Perrea DN, et al. Managements of endocrine disease: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: A systematic review and meta-analysis. Eur J Endocrinol 2017;176:25- 9.
15. KarakÃ¶se M, Gungunes A, Cakal E, Ozbek M, Delibasi T. Frequency of nodular goiter and autoimmune thyroid disease and association of these disorders with insulin resistance in polycystic ovary syndrome. J Turk Ger Gynecol Assoc 2017;18:85-9.
16. Mohammed S, Awooda HA, Rayis DA, Hamdan HZ, Adam I, Lutfi MF, et al. Thyroid function/antibodies in Sudanese women with polycystic ovarian disease. Obstet Gynecol Sci 2017;60:187-92.
17. Sinha U, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK, et al. Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. Indian J Endocrinol Metab 2013;17:304-9.
18. Hennessey J, Espaillat R. Diagnosis and management of subclinical hypothyroidism in elderly adults: A review of the literature. J Am Geriatr Soc 2015;63:1663-73.
19. Katulski K, CzyÅ¼yk A, MÄ™czekalski B. Bone mineral density in women with polycystic ovary syndrome. J Endocrinol Invest 2014;37:1219-24.
20. Kumar A, Naidu JN, Satyanarayana U, Ramalingam K, Anitha M. Metabolic and endocrine characteristics of indian women with polycystic ovary syndrome. Int J Fertil Steril 2016;10:22-8.
21. Al-Ruthia YS, Al-Mandeel H, Al-Sanawi H, Mansy W, Al-Gasem R, Al-Mutairi L, et al. Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome. Saudi Pharm J 2017;25:795-800.
22. Aghadavod E, Mollaei H, Nouri M, Hamishehkar H. Evaluation of Relationship between body mass index with Vitamin D receptor gene expression and Vitamin D levels of follicular fluid in overweight patients with polycystic ovary syndrome. Int J Fertil Steril 2017;11:105-11.
23. Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril 2012;97:7-12.
24. Zaica R. MCP-1 (monocyte chemotactic protein-1) and harpin molecules in inflammation processes 3T. Bio Med 2014;44:213-7.
25. Julie T. Polycystic ovary syndrome: Why are women at increased risk of Type 2 diabetes? J Diabetes Nurs 2016;20:92-7.
26. Jesintha M. Genetic variations in polycystic ovarian syndrome disease. Asian J Pharm Clin Res 2015;8:1-6.
27. Belinda G. Polycystic ovary syndrome (PCOS) - From in utero to menopause. Diabetes Obes Int J 2016;1:1-6.
28. Azziz R. Introduction: Determinants of polycystic ovary syndrome. Fertil Steril 2016;106:4-5.
29. Joham AE, Hutchison SK, Harrison CL. Polycystic ovary syndrome, obesity, and pregnancy. Semin Reprod Med 2016;34:93-101.
30. Sahin M, Demircioglu D, Oguz A, Tuzun D, Sarica MA, Inanc E, et al. Does insulin resistance increase thyroid volume in patients with polycystic ovary syndrome? Arch Endocrinol Metab 2017;61:145- 51.
31. Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, IbÃ¡Ã±ez L, et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 2015;83:376-89.
32. Ahmed M. Polycystic ovarian syndrome: Insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. Kabel J Pharma Rep 2016;1:1-5.
33. Alvina R, Kansra MD. Polycystic ovary syndrome in adolescents. JCOM 2016;23:233-9.
34. AlFaisal AH, Al-Deresawi MS. The correlation between thyroid hormones, reproductive hormones, body mass index (BMI) and hirsute in Iraqi women with polycystic ovary syndrome (PCOS). J Univ Anbar Pure Sci 2013;7:1-6.
35. Zou S, Sang Q, Wang H, Feng R, Li Q, Zhao X. Common genetic variation in CYP1B1 is associated with concentrations of T(4), FT(3) and FT(4) in the sera of polycystic ovary syndrome patients. Mol Biol Rep 2013;40:3315-20.
36. Abd El-Hafez HA, Elrakhawy MM, El-Aziz SA, El-Eshmawy MM. Thyroid function and volume are associated with anthropometric measurements and Ä±nsulin resistance in Egyptian women with polycystic ovary syndrome. J Diabetes Metab 2013;4:1-5.
37. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Endocrine society. Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-92.
38. Yin D, Ruan X, Tian X, Du J, Zhao Y, Cui Y, et al. The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. Gynecol Endocrinol 2017;33:332-5.
39. Lan C, Tan Y, Cao P. Relationship of thyroid stimulating hormone with sex hormones in patients with polycystic ovary syndrome: A single-center, retrospective observational study. Int J Clin Exp Pathol 2017;10:5989-93.
40. Singla R, Gupta Y, Khemani M, Aggarwal S. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian J Endocrinol Metab 2015;19:25-9.
41. Homeira R, Asghar S., Mahmoud A., Seyed M., Fahimeh R., Hajieh S.. Association of thyroid stimulating hormone in women with poly cystic ovary syndrome and non poly cystic ovary syndrome with insulin resistance. Int J Pharm Technol 2016;8:11634-41.
42. Danfeng D, Xuelian L. The relationship between thyroiditis and polycystic ovary syndrome: A meta-analysis. Int J Clin Exp Med 2013;6:880-9.
43. Teizo Y. The production of monocyte chemoattractant protein-1 (MCP 1)/CCL2 in tumor microenvironments. Cytokine 2017;98:71-8.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.